CSIMarket
 
Advanced Container Technologies Inc   (ACOL)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 52
 Employees 22
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Advanced Container Technologies Inc

Through D&C Distributors LLC, we are in the business of selling proprietary plastic medical grade containers under the registered trademark “Medtainer®" that can store pharmaceuticals, herbs, teas and other solids or liquids, some of which can grind solids and shred herbs. We have received child safety certification for our 20-dram container and we are focusing our marketing efforts on drug stores and drug store chains, veterinarians and veterinary distributors and other distributors and end users. Through D&C Printing LLC, we are in the business of private labeling and branding for purchasers of containers and other products.

Through D&C Distributors LLC and and D&C Printing LLC, we are in the business of selling and distributing patented containers that can store, grind and shred pharmaceuticals, herbs, teas and other solids or liquids that are described under the caption “Description of Business – Products – The Medtainer®.” We provide custom printing of labeling for our products and products manufactured by others, as described under the caption, “Description of Business – Printing.”

We market directly to businesses through our phone room to the retail public through internet sales and, and to wholesalers and other businesses who resell our products to other businesses and end users.

Some of our products can be utilized for marijuana-related purposes. In light of the facts that the possession and use of marijuana have been legalized, subject to varying restrictions, in many states and that several other states are considering such legalization, we believe that our products may be of interest to a large number of users of marijuana in and we advertise our products on our website and elsewhere as suitable for that purpose. However, since we do not seek information from our customers who are end users as to how they intend to utilize our products and have no similar knowledge respecting end users of products sold through our distributor, we are unable to determine the extent of its use in connection with the storage and grinding of marijuana or any other purpose. We believe that marketing these products subjects us to the following risks.

The use of marijuana for medical and recreational use is lawful in many states, but under United States federal law and the laws of the other states, the possession, use, cultivation, storage, processing and/or transfer of marijuana is illegal. Federal and state law enforcement authorities have prosecuted persons engaged in these activities. While we do not believe that we engage in any of these activities, any of these law enforcement authorities might bring an action against us in connection with the engagement of others in them, including, but not limited, to a claim of aiding and abetting their criminal activities. Such an action would have a material and adverse effect on our business and operations.


· Under United States federal law, it is unlawful to sell or offer for sale, to use the mails or any other facility of interstate commerce to transport or to import or export drug paraphernalia. The term “drug paraphernalia” includes any equipment, product or material of any kind which is primarily intended or designed for use in manufacturing, compounding, converting, concealing, producing, processing, preparing, injecting, ingesting, inhaling, or otherwise introducing into the human body a controlled substance. One of the factors that these authorities may consider in determining whether our products are drug paraphernalia are our national and local advertising concerning its use and we have advertised our products as usable for marijuana-related purposes. However, we do not believe that our products were designed or are intended for any of these purposes or that our products are drug paraphernalia, as defined in federal law, and we are promoting our products primarily to be used for other purposes. If federal authorities were to take a different view, they might bring a criminal action against us. Such an action would have a material and adverse effect on our business and operations. During the administration of President Barack H. Obama, enforcement of such federal law was relaxed, but there have been indications that the administration of President Donald J. Trump may enforce it differently. We are presently unable to predict what effect, if any, this change, if it occurs, would have on us or our business.



   Company Address: 1620 Commerce St. Corona 92878 CA
   Company Phone Number: 381-2555   Stock Exchange / Ticker: ACOL
   ACOL is expected to report next financial results on April 14, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TUP   -0.43%    
• View Complete Report
   



Cnbx Pharmaceuticals Inc

The Biotechnology & Pharmaceuticals company added great story for the stock market, presenting a genuine rise in fiscal interval ending August 31 2022 with operating deficit of $-0.478354 millions

The Biotechnology & Pharmaceuticals industry consultants begin to analyze the fourth quarter of 2022 numbers. Presently they observe operating deficit of $-0.478354 millions, from the CNBK, as it has not mentioned any top-line thus far, for the own June to August 31 2022 reporting period.

Ncino Inc

Deficit bigger than a year prior at the Ncino Inc amid the fiscal span closing October 31 2022

For the fiscal span closing October 31 2022 NCNO Losses have widen of $-0.21 per share compare to $-0.14 a year prior and EPS improved from $-0.25 per share from the preceding quarter.

Sales rose strongly by 50.346 % to $105.30 millions from $70.04 millions in the comparable quarter a year prior and sequentially Sales surged by 5.69 % from $99.63 millions.

Bakkt Holdings Inc

Bakkt Holdings Inc published Sales of $12.86 millions, in the third quarter of 2022 earnings season

the Software & Programming company disclosed $12.86 millions, in Sales in the third quarter of 2022 earnings season.

Coro Global Inc

Coro Global Inc released Sales of $0.000662 millions, in the fiscal span ending June 30 2021

the Software & Programming company has seen $0.000662 millions, in Sales in the second quarter of 2021 earnings season.